Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
A New Therapeutic Candidate for Cardiovascular Diseases: Berberine
Patients should be aware that key safety considerations include: Hypersensitivity to the active substance or excipients Pregnancy or breastfeeding Risk of pancreatitis and gallbladder disease Potential for dehydration with severe gastrointestinal side effects A thorough medical assessment, including review of current medications and comorbidities, is essential before initiating treatment
2016 Agreement with GE Healthcare Ferozsons Laboratories signed an agreement with GE Healthcare to become a channel partner for the marketing and sale of value-segment medical devices in Pakistan
Food & Drug Administration Compounding inspections and oversight frequently asked questions, U.S
A second head-to-head comparison trial between lixisenatide and liraglutide was performed in 60 subjects with T2DM [18]
US$ 28.64
US$ 27.61
US$ 25.91
US$ 20.35
US$ 20.30
US$ 27.39
US$ 24.89
US$ 20.19
US$ 20.91
US$ 21.85
US$ 28.73
US$ 20.22
US$ 20.62
